PMGC Holdings Inc. ELAB
portfolio of four (4) wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors:
Inc. ("Northstrive Biosciences") is a biopharmaceutical company focusing on the development and acquisition of cutting-edge
aesthetic medicines and therapeutic products. Our lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to
address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $590.1K | — | $1.7M | $766.3K | — |
| Cost of revenue | $404.8K | — | $1.7M | $319.0K | — |
| Gross profit | $185.3K | — | $1.1M | $447.3K | — |
| R&D | $147.0K | $104.7K | $7.4K | $228.7K | — |
| SG&A | $2.2M | $1.1M | $347.7K | $1.0M | — |
| Total operating expenses | $7.1M | $3.7M | $1.1M | $2.2M | — |
| Interest expense | $257.6K | $735.2K | $19.5K | $2.6K | — |
| Pre-tax income | -$7.7M | -$4.0M | — | — | — |
| Income tax | $31.0K | — | — | — | — |
| Net income | -$7.7M | -$6.2M | -$4.3M | -$1.8M | — |
| EPS, basic | — | — | -0.40 | -0.19 | — |
| EPS, diluted | — | — | -0.40 | -0.19 | — |
| Shares, diluted (wtd. avg.) | 20,352 | 947 | 7,676 | 9.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $5.4M | $4.0M | $3.3M | $1.2M | $411.9K |
| Short-term investments | $572.1K | — | — | — | — |
| Receivables | $245.4K | $5.3K | $3.1K | $12.9K | — |
| Inventory | $95.1K | — | $495.7K | $230.1K | — |
| Total current assets | $6.9M | $6.1M | $4.9M | $1.6M | — |
| Property, plant and equipment | $885.5K | $1.1K | $1.7K | $53.5K | — |
| Goodwill | $977.8K | — | — | — | — |
| Other intangibles | $2.9M | $2.8M | — | — | — |
| Total assets | $12.9M | $9.0M | $5.2M | $1.9M | — |
| Accounts payable | $697.6K | $481.0K | $134.0K | $244.7K | — |
| Total current liabilities | $3.9M | $1.8M | $1.3M | $588.3K | — |
| Total liabilities | $5.0M | $2.3M | $1.4M | $760.9K | — |
| Retained earnings | -$21.0M | -$13.3M | -$7.0M | -$2.7M | — |
| Total equity | $7.8M | $6.7M | $3.8M | $1.1M | $450.6K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.9M | -$5.5M | -$4.6M | -$1.6M | — |
| Depreciation and amortisation | $96.7K | $12.9K | $11.6K | $6.5K | — |
| Stock-based compensation | -$19.2K | $97.2K | $487.7K | $171.9K | — |
| Capital expenditure | $442.3K | $9.2K | $11.2K | — | — |
| Investing cash flow | -$2.8M | -$610.6K | -$11.2K | -$32.0K | — |
| Financing cash flow | $10.1M | $6.8M | $6.7M | $2.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-035937.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $766.3K | $1.7M | — | $590.1K |
| Gross profit | — | $447.3K | $1.1M | — | $185.3K |
| Net income | — | -$1.8M | -$4.3M | -$6.2M | -$7.7M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
- Shareholder rights changed Item 3.03
- Charter or fiscal year changed Item 5.03
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |